[Objectives]To make an evaluation of the efficacy and safety of Biyuan Tongqiao Granule in the treatment of chronic sinusitis in children,and provide evidence-based medical reference for clinical use.[Methods]Database...[Objectives]To make an evaluation of the efficacy and safety of Biyuan Tongqiao Granule in the treatment of chronic sinusitis in children,and provide evidence-based medical reference for clinical use.[Methods]Databases such as Chinese Biomedical Literature Service System(SinoMed),China Knowledge Infrastructure(CNKI),Wanfang Digital Journal Full-text Database(WF),VIP Database(VIP),EmBase,PubMed,Science Direct,and Cochrane Library were used to collect the clinical randomized controlled trials of Biyuan Tongqiao Granule in children with chronic sinusitis published since the creation of databases.The quality of the included literature was evaluated and the data were extracted.The data was analyzed using Review Manager 5.3 software for meta-analysis,and descriptive analysis was performed for studies that could not be combined.The GRADE method was applied to evaluate the quality of evidence.[Results]A total of 12 studies were included,including 1645 cases of patients.The analysis results show that compared with the control group,Biyuan Tongqiao Granule has an excellent curative effect on children with chronic sinusitis and has a lower incidence of adverse reactions.The GRADE evidence level indicated that the sinus CT scan lesion score was intermediate evidence,and the visual analog score,endoscopic mucosal morphology score,and total effective rate were low-level evidence.[Conclusions]Biyuan Tongqiao Granule has a significant effect in treating chronic sinusitis in children and does not increase the incidence of adverse reactions,but its efficacy and safety need support of more high-quality studies.展开更多
目的 探讨丙酸倍氯米松鼻喷雾剂与鼻渊合剂联合治疗风寒湿型变应性鼻炎的临床效果。方法 选取2021年6月至2023年5月江苏省海安市中医院耳鼻喉科收治的126例风寒湿型变应性鼻炎患者为研究对象,根据随机数字表法将其分为西药组(丙酸倍氯米...目的 探讨丙酸倍氯米松鼻喷雾剂与鼻渊合剂联合治疗风寒湿型变应性鼻炎的临床效果。方法 选取2021年6月至2023年5月江苏省海安市中医院耳鼻喉科收治的126例风寒湿型变应性鼻炎患者为研究对象,根据随机数字表法将其分为西药组(丙酸倍氯米松)、中药组(鼻渊合剂)及联合组(丙酸倍氯米松联合鼻渊合剂),各42例。西药组采取丙酸倍氯米松鼻喷雾剂治疗,中药组采取鼻渊合剂治疗,联合组则采取两药联合治疗。治疗4周后,比较三组临床疗效及三组治疗前后的鼻黏膜症状[鼻症状视觉模拟评分法(VAS)评分、鼻症状总积分表(TNSS)、鼻伴随症状总分表(TNNSS)]、鼻黏膜炎症标志物[黏蛋白-5AC(MUC5AC)、白细胞介素-6(IL-6)、γ干扰素(IFN-γ)]、鼻功能[总鼻气道阻力(NAR)、鼻腔最小横断面积(NMCA)和0~5 cm鼻腔容积(0~5 cm NCV)]。结果 联合组疗效优于西药组和中药组(P<0.05)。治疗后,三组鼻症状VAS、TNSS、TNNSS评分均低于治疗前,且联合组低于西药组和中药组(P<0.05)。治疗后,三组MUC5AC、IL-6水平均低于治疗前,IFN-γ水平高于治疗前,且联合组MUC5AC、IL-6水平低于西药组和中药组,IFN-γ水平高于西药组和中药组(P<0.05)。治疗后,三组NAR低于治疗前,NMCA、0~5 cm NCV高于治疗前,且联合组NAR低于西药组和中药组,NMCA、0~5 cm NCV高于西药组和中药组(P<0.05)。结论 丙酸倍氯米松鼻喷雾剂与鼻渊合剂联合治疗风寒湿型变应性鼻炎显示出良好的效果,可有效减轻鼻黏膜炎症反应,提高患者的生活质量,在临床上具有较大的推广价值。展开更多
基金Supported by National Key Subject of Drug Innovation(No.2018ZX09201010-005)National Key Research and Development Program of China(No.2019YFC1711200-05).
文摘[Objectives]To make an evaluation of the efficacy and safety of Biyuan Tongqiao Granule in the treatment of chronic sinusitis in children,and provide evidence-based medical reference for clinical use.[Methods]Databases such as Chinese Biomedical Literature Service System(SinoMed),China Knowledge Infrastructure(CNKI),Wanfang Digital Journal Full-text Database(WF),VIP Database(VIP),EmBase,PubMed,Science Direct,and Cochrane Library were used to collect the clinical randomized controlled trials of Biyuan Tongqiao Granule in children with chronic sinusitis published since the creation of databases.The quality of the included literature was evaluated and the data were extracted.The data was analyzed using Review Manager 5.3 software for meta-analysis,and descriptive analysis was performed for studies that could not be combined.The GRADE method was applied to evaluate the quality of evidence.[Results]A total of 12 studies were included,including 1645 cases of patients.The analysis results show that compared with the control group,Biyuan Tongqiao Granule has an excellent curative effect on children with chronic sinusitis and has a lower incidence of adverse reactions.The GRADE evidence level indicated that the sinus CT scan lesion score was intermediate evidence,and the visual analog score,endoscopic mucosal morphology score,and total effective rate were low-level evidence.[Conclusions]Biyuan Tongqiao Granule has a significant effect in treating chronic sinusitis in children and does not increase the incidence of adverse reactions,but its efficacy and safety need support of more high-quality studies.
文摘目的 探讨丙酸倍氯米松鼻喷雾剂与鼻渊合剂联合治疗风寒湿型变应性鼻炎的临床效果。方法 选取2021年6月至2023年5月江苏省海安市中医院耳鼻喉科收治的126例风寒湿型变应性鼻炎患者为研究对象,根据随机数字表法将其分为西药组(丙酸倍氯米松)、中药组(鼻渊合剂)及联合组(丙酸倍氯米松联合鼻渊合剂),各42例。西药组采取丙酸倍氯米松鼻喷雾剂治疗,中药组采取鼻渊合剂治疗,联合组则采取两药联合治疗。治疗4周后,比较三组临床疗效及三组治疗前后的鼻黏膜症状[鼻症状视觉模拟评分法(VAS)评分、鼻症状总积分表(TNSS)、鼻伴随症状总分表(TNNSS)]、鼻黏膜炎症标志物[黏蛋白-5AC(MUC5AC)、白细胞介素-6(IL-6)、γ干扰素(IFN-γ)]、鼻功能[总鼻气道阻力(NAR)、鼻腔最小横断面积(NMCA)和0~5 cm鼻腔容积(0~5 cm NCV)]。结果 联合组疗效优于西药组和中药组(P<0.05)。治疗后,三组鼻症状VAS、TNSS、TNNSS评分均低于治疗前,且联合组低于西药组和中药组(P<0.05)。治疗后,三组MUC5AC、IL-6水平均低于治疗前,IFN-γ水平高于治疗前,且联合组MUC5AC、IL-6水平低于西药组和中药组,IFN-γ水平高于西药组和中药组(P<0.05)。治疗后,三组NAR低于治疗前,NMCA、0~5 cm NCV高于治疗前,且联合组NAR低于西药组和中药组,NMCA、0~5 cm NCV高于西药组和中药组(P<0.05)。结论 丙酸倍氯米松鼻喷雾剂与鼻渊合剂联合治疗风寒湿型变应性鼻炎显示出良好的效果,可有效减轻鼻黏膜炎症反应,提高患者的生活质量,在临床上具有较大的推广价值。
